Mimedx (MDXG) EBIT Margin (2011 - 2026)

Mimedx has disclosed EBIT Margin across 16 years of filings, most recently posting 27.21% for Q1 2026.

• EBIT Margin for Q1 2026 came in at 27.21%, down 3656.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 10.17% (down 513.0% YoY), and the FY2025 annual result was 15.26%, down 161.0% from the prior year.
• EBIT Margin came in at 27.21% for Q1 2026 at Mimedx, down from 17.85% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 26.89% in Q2 2024 to a low of 27.21% in Q1 2026.
• The 5-year median for EBIT Margin is 13.28% (2024), against an average of 6.97%.
• Across the five-year window, EBIT Margin soared 2775 bps in 2023 and sank 3656 bps in 2026, its largest moves.
• Mimedx's EBIT Margin stood at 15.21% in 2022, then climbed by 17 bps to 17.84% in 2023, then slumped by 33 bps to 11.9% in 2024, then surged by 50 bps to 17.85% in 2025, then plunged by 252 bps to 27.21% in 2026.
• The last three EBIT Margin figures came in at 27.21% (Q1 2026), 17.85% (Q4 2025), and 19.51% (Q3 2025), per Business Quant data.